An observational study in Prostate Cancer (Diagnosis), sponsored by First Affiliated Hospital of Guangxi Medical University. Not yet recruiting at 6 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by First Affiliated Hospital of Guangxi Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 542 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 52 of them phase 3. Prostatic Neoplasms · China.
Among the 542 studies in Prostatic Neoplasms with a site in China, this one is the 5th largest by planned enrollment of the 106 observational ones that give a count, is one of 83 that started in 2026, is one of 106 observational ones, reaches primary completion later than 289 of the 341 other live ones, and was the 531st registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →281 of the 542 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:
Norroy Bioscience Co., LTD · Sites in China
Ages 18+ · Men only
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+ · Men only
Yong He · Sites in China
Ages 18–90 · Men only
TransThera Sciences (Nanjing), Inc. · Sites in China
Ages 18+ · Men only
Janssen Research & Development, LLC · Sites in China, United States, Australia and 1 more country
Ages 18+ · Men only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
542 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 149 · Phase 2 146 · Phase 3 88 · Phase 4 7
First in 2003; this study’s year is marked. 83 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 100 across the 436 interventional studies, 300 across the 106 observational. Of the 110 that completed or were terminated, 23 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
200 of 542 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Guangxi Medical University is the lead sponsor of 42 studies on the registry; 26 are open to participants now.
First Affiliated Hospital of Guangxi Medical University has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
95 of the studies in Prostatic Neoplasms with a site in China that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03258320Phase 3Shanghai Jiao Tong University School of MedicineA Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients | 2026-12 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT07241416Phase 3Jiangsu HengRui Medicine Co., Ltd.A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer | 2027-03 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
Add all 95 to your calendar (.ics) → With an account.
Among the 542 studies in Prostatic Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter clinical study is evaluating CascadeDiagnose Prostate MRI, an artificial-intelligence software tool that analyzes standard prostate MRI scans-T2-weighted, diffusion-weighted, and ADC images-to help radiologists detect suspicious prostate lesions, estimate cancer risk, and distinguish prostate cancer from benign conditions. The study will take place at six hospitals in Guangxi and plans to enroll at least 2,000 eligible men aged 18 or older who have had prostate MRI and have confirmed pathology results. It includes a retrospective phase using existing records and a prospective phase in which participants provide written informed consent. The main goals are to measure the system's diagnostic accuracy (AUC, sensitivity, and specificity), compare it with readings by radiologists, assess safety and rates of rejected or indeterminate results, and see whether it improves reading efficiency or helps reduce unnecessary biopsies. To protect patient privacy, raw MRI, medical-record, and pathology data remain inside each hospital; only de-identified, encrypted intermediate results are shared through a secure distributed network. The study requires ethics approval and trial registration before enrollment, and its results may help determine whether this AI tool is safe and effective for clinical use.
This study addresses a clinically important gap in prostate cancer diagnosis: although multiparametric MRI is central to detection, PI-RADS interpretation is subject to substantial inter-reader variability and often yields suboptimal discrimination between clinically significant cancer and benign mimics. CascadeDiagnose Prostate MRI is a cascaded deep-learning system that first detects and segments prostatic lesions on T2-weighted, diffusion-weighted, and apparent diffusion coefficient sequences, and then performs malignant-benign classification and Gleason-based risk stratification. The system is designed to provide interpretable, traceable outputs-including sequence and slice references, zonal localization, confidence scores, Grad-CAM heatmaps, and segmentation masks-and to return indeterminate or rejection results when image quality, data integrity, or model confidence is insufficient, rather than forcing a diagnosis. The study will evaluate this system across six tertiary hospitals with diverse MRI vendors, field strengths, and radiologist experience, using both retrospective and prospective validation. A central methodological feature is the Guangxi-wide medical-sharing distributed trusted computing network. Each hospital operates a local edge node; raw MRI, clinical, and pathological data remain within the hospital and are never centrally uploaded. Only de-identified, SM4-encrypted intermediate features and gradient parameters are transmitted to a regional aggregation node for federated model collaboration and multi-center statistical summarization, implementing the principle of "don't move data; move computing power." In the prospective phase, AI analysis and human reading are performed under a locked system version, with pre-specified rules for clinician access to AI outputs. Reading sessions include AI-alone, radiologist-alone, and AI-assisted interpretations to assess diagnostic performance, workflow efficiency, and safety in a real-world setting. The study incorporates rigorous quality control, including local image-quality review, anti-tampering receipts, cross-node audit trails, and full traceability of data, model, threshold, inference, and manual-review versions. It is intended to generate regulatory-grade evidence on diagnostic accuracy, generalization, rejection behavior, and clinical utility while demonstrating a compliant, privacy-preserving infrastructure for multi-center evaluation of healthcare AI.
The study will enroll at least 2,000 eligible men aged 18 years or older with complete prostate MRI (T2WI, DWI, ADC), definitive pathology with Gleason score, and full clinical data including PSA, age, and medical history-approximately 1,500 retrospectively and 500 prospectively. Key exclusions are severe image artifacts, prior prostate biopsy, surgery, radiotherapy or endocrine therapy, other malignancies, missing key MRI or reference-standard data, and severe systemic disease interfering with assessment. Written informed consent is required prospectively, with a possible waiver for retrospective data per local ethics committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prostate cancer
Benign prostatic hyperplasia
Adverse Events
All adverse events associated with system usage are documented
Time frame: up to 24 weeks
Area under the receiver operating characteristic curve (AUC)
overall diagnostic performance for discriminating prostate cancer from benign lesions
Time frame: up to 24 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data (IPD) will not be shared. This study is conducted under a distributed trusted computing network in which raw MRI, clinical, and pathological data remain stored and processed locally within each participating hospital and are never exported or centrally aggregated. Cross-institutional transmission is limited to de-identified, encrypted intermediate features and gradient parameters, and the aggregation node cannot reconstruct original patient images or personally identifiable information. Sharing IPD would therefore violate the study's data-sovereignty and privacy-protection framework, the requirements of China's Personal Information Protection Law and Data Security Law, and the terms of the multi-center ethics approvals. Only de-identified aggregated summary statistics and study-level results will be reported.
Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 26 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Guangxi Medical University